These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 1944244)

  • 1. Structure-activity relationships of phenothiazines and related drugs for inhibition of protein kinase C.
    Aftab DT; Ballas LM; Loomis CR; Hait WN
    Mol Pharmacol; 1991 Nov; 40(5):798-805. PubMed ID: 1944244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance.
    Ford JM; Prozialeck WC; Hait WN
    Mol Pharmacol; 1989 Jan; 35(1):105-15. PubMed ID: 2563302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of novel imidazole-substituted dipeptide amides as potent and selective inhibitors of Candida albicans myristoylCoA:protein N-myristoyltransferase and identification of related tripeptide inhibitors with mechanism-based antifungal activity.
    Devadas B; Freeman SK; Zupec ME; Lu HF; Nagarajan SR; Kishore NS; Lodge JK; Kuneman DW; McWherter CA; Vinjamoori DV; Getman DP; Gordon JI; Sikorski JA
    J Med Chem; 1997 Aug; 40(16):2609-25. PubMed ID: 9258368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta.
    Jirousek MR; Gillig JR; Gonzalez CM; Heath WF; McDonald JH; Neel DA; Rito CJ; Singh U; Stramm LE; Melikian-Badalian A; Baevsky M; Ballas LM; Hall SE; Winneroski LL; Faul MM
    J Med Chem; 1996 Jul; 39(14):2664-71. PubMed ID: 8709095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of rodent protein kinase C by the anticarcinoma agent dequalinium.
    Rotenberg SA; Smiley S; Ueffing M; Krauss RS; Chen LB; Weinstein IB
    Cancer Res; 1990 Feb; 50(3):677-85. PubMed ID: 2297708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.
    Showalter HD; Sercel AD; Leja BM; Wolfangel CD; Ambroso LA; Elliott WL; Fry DW; Kraker AJ; Howard CT; Lu GH; Moore CW; Nelson JM; Roberts BJ; Vincent PW; Denny WA; Thompson AM
    J Med Chem; 1997 Feb; 40(4):413-26. PubMed ID: 9046331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
    Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
    Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MDL 27,032 [4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone], an active site-directed inhibitor of protein kinase C and cyclic AMP-dependent protein kinase that relaxes vascular smooth muscle.
    Robinson PJ; Cheng HC; Black CK; Schmidt CJ; Kariya T; Jones WD; Dage RC
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1392-8. PubMed ID: 2175806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naphthalenesulfonamides as calmodulin antagonists and protein kinase inhibitors.
    Inagaki M; Kawamoto S; Itoh H; Saitoh M; Hagiwara M; Takahashi J; Hidaka H
    Mol Pharmacol; 1986 Jun; 29(6):577-81. PubMed ID: 2872589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
    Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
    J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines.
    Ford JM; Bruggemann EP; Pastan I; Gottesman MM; Hait WN
    Cancer Res; 1990 Mar; 50(6):1748-56. PubMed ID: 1968358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The primary in vitro anticancer activity of "half-mustard type" phenothiazines in NCI's revised anticancer screening paradigm.
    Wuonola MA; Palfreyman MG; Motohashi N; Kawase M; Gabay S; Gupta RR; Molnár J
    Anticancer Res; 1998; 18(1A):337-48. PubMed ID: 9568100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and protein kinase C inhibitory activities of balanol analogs with replacement of the perhydroazepine moiety.
    Lai YS; Mendoza JS; Jagdmann GE; Menaldino DS; Biggers CK; Heerding JM; Wilson JW; Hall SE; Jiang JB; Janzen WP; Ballas LM
    J Med Chem; 1997 Jan; 40(2):226-35. PubMed ID: 9003521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of the antiproliferative action of diphenylmethane-derivative antiestrogen binding site ligands with antagonism of histamine binding but not of protein kinase C-mediated phosphorylation.
    Brandes LJ; Gerrard JM; Bogdanovic RP; Lint DW; Reid RE; LaBella FS
    Cancer Res; 1988 Jul; 48(14):3954-8. PubMed ID: 3164253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical correlates of the antitumor and antimitochondrial properties of gossypol enantiomers.
    Benz CC; Keniry MA; Ford JM; Townsend AJ; Cox FW; Palayoor S; Matlin SA; Hait WN; Cowan KH
    Mol Pharmacol; 1990 Jun; 37(6):840-7. PubMed ID: 2193225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KT5926, a potent and selective inhibitor of myosin light chain kinase.
    Nakanishi S; Yamada K; Iwahashi K; Kuroda K; Kase H
    Mol Pharmacol; 1990 Apr; 37(4):482-8. PubMed ID: 2325635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
    Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
    J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of selective bisubstrate-based inhibitors against protein kinase C (PKC) isozymes by using dynamic peptide microarrays.
    Poot AJ; van Ameijde J; Slijper M; van den Berg A; Hilhorst R; Ruijtenbeek R; Rijkers DT; Liskamp RM
    Chembiochem; 2009 Aug; 10(12):2042-51. PubMed ID: 19618415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
    Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel highly specific and potent inhibitor of calmodulin-dependent protein kinase II.
    Ishida A; Kameshita I; Okuno S; Kitani T; Fujisawa H
    Biochem Biophys Res Commun; 1995 Jul; 212(3):806-12. PubMed ID: 7626114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.